Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday’s Mid-Day Session
Shares of Ovid Therapeutics Inc (NASDAQ:OVID) dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed…
12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers Mustang Bio (NASDAQ:MBIO) stock moved upwards by 307.9% to $0.53 during Monday’s regular session. The company’s market…
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers Liquidia (NASDAQ:LQDA) stock rose 12.7% to $14.5 during Friday’s after-market session. The market value of their outstanding…
Atara Biotherapeutics Submits Tabelecleucel BLA For Treatment Of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease With U.S. FDA; Acceptance Of BLA Will Trigger $20M Milestone Payment From Pierre Fabre Laboratories, With Potential…
First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug AdministrationIf Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLDAcceptance of BLA Will Trigger $20 Million Milestone Payment
12 Health Care Stocks Moving In Tuesday’s After-Market Session
Gainers Clover Health Investments (NASDAQ:CLOV) shares increased by 14.9% to $0.85 during Tuesday’s after-market session. The market value…
12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers Kineta (NASDAQ:KA) shares increased by 24.3% to $0.67 during Monday’s after-market session. The market value of their…
Atara Biotherapeutics: Q4 Earnings Insights
Atara Biotherapeutics (NASDAQ:ATRA) reported its Q4 earnings results on Thursday, March 28, 2024 at 08:30 AM. Here’s what…
Atara Biotherapeutics Announces Submission Of Investigational New Drug Application For ATA3219 For Treatment Of Lupus Nephritis
ATA3219 is an Allogeneic CAR T-Cell Therapy Targeting CD19+ B Cells to Potentially Address the Root Cause of Lupus Nephritis (LN)ATA3219 Is Designed to Combine the Natural Biology of Unedited T Cells and the Benefits of
Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket
Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading.
4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150 demonstrating favorable tolerability & clinical activity in wet AMD.
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers InVivo Therapeutics Hldg (NASDAQ:NVIV) shares moved upwards by 30.1% to $0.41 during Friday’s after-market session. The market…